LSD shows promise in reducing anxiety; study finds one dose can ease symptoms for up to three months: Here's what it means

LSD, the psychedelic tab once relegated to 1960s counterculture and verboten for decades, is making a rather unexpected comeback—but this time in the world of medicine. A recent study by biotech company MindMed found that a single dose of LSD significantly reduced anxiety symptoms in people with generalized anxiety disorder, with effects lasting up to three months. The findings of the has been published in the published by the Journal of the American Medical Association.Here’s the kicker: unlike earlier trials that bundled LSD with long therapy sessions, this one was bold and minimalistic just a measured dose, no talk therapy. The goal? Judge the drug’s strength on its own. About 200 folks with mild to severe anxiety were given various doses of LSD or a placebo. The standout was a 100-microgram dose: about 65% of participants still felt better three months later, and roughly half were symptom-free—talk about promising. Of course, it wasn’t all sunshine and rainbows—some experienced vivid hallucinations, nausea, or headaches—but these side effects paled compared to the anxiety relief. Still, the study did highlight a few obvious issues, most participants could tell whether they got the real drug or a dummy pill, making the study “unblinded” and muddying the results. A few people also dropped out, which shrunk the sample size. MindMed isn’t stopping here. It’s setting up big Phase 3 trials to confirm these results over longer periods, aiming eventually for FDA approval. If things go well, LSD could be legalized under medical supervision for anxiety treatment. This is huge because it signals a broader shift: psychedelics aren’t just party props anymore, they’re being eyed as serious mental health tools. Even figures like RFK Jr. and other officials are showing support for fast-tracking these treatments, especially for veterans and others with conditions that don’t respond well to traditional therapies. “I see this paper as a clear step in the direction of reviving that old research, applying our modern standards and determining what are the real costs and benefits of these compounds,” said Frederick Barrett, who directs Johns Hopkins University’s psychedelic center told AP news. He was not involved in the research.Still, there is caution. Without solid blinding and more extensive testing, it’s tough to separate the drug’s real effects from placebo—or from the “wow” factor of the experience itself. Let’s not forget psychedelics can trigger intense emotional states that may require therapy to process.